

# BC Cancer Protocol Summary for Topical Therapy for Ocular Malignancies Using Fluorouracil Eye Drops

**Protocol Code**

*OCFU*

**Tumour Group**

*Ocular and orbital*

**Contact Physician**

*Dr. Katherine Paton  
Dr. Vivian Yin*

## ELIGIBILITY:

- malignant melanoma of the conjunctiva
- ocular surface squamous neoplasia (OSSN), also known as conjunctival-corneal intraepithelial neoplasia (CCIN)

## EXCLUSIONS:

- Pre-malignant primary acquired melanosis

## TESTS:

- Baseline: biopsy of lesion
- If clinically indicated: incomplete regression

## PREMEDICATIONS:

- no antiemetics required

## TREATMENT<sup>1,2,3</sup>:

Drug	Dose	BC Cancer Administration Guideline
fluorouracil 1% eye drops	3 to 4 times daily for 4 to 5 days each week for 4-6 weeks*	Topical

\* Alternatively, QID daily for one week, then three weeks off, for 4 to 6 cycles

Preparation of fluorouracil 1% (10 mg/mL) eye drops:

- Withdraw 2 mL from 50 mg/mL vial of fluorouracil
- Transfer the 2 mL (100 mg) to a sterile 15 mL eye dropper bottle
- Add 8 mL NS to the eye dropper bottle to give a concentration of 10 mg/mL (1%)

Final product is stable for 7 days at room temperature and refrigerated.<sup>4</sup>

## PRECAUTIONS:

1. Temporary occlusion of punctum
2. Petrolatum (e.g., Vaseline®) barrier on lid to prevent burning

**Call Dr. Katherine Paton or Dr. Vivian Yin at Eye Care Centre @ (604) 875-5201 with any problems or questions regarding this treatment program.**

**References:**

1. Al Bayyat G, Arreaza-Kaufman D, Venkateswaran N, Galor A, Karp CL. Update on pharmacotherapy for ocular surface squamous neoplasia. *Eye Vis* 2019;6:24.
2. Venkateswaran N, Mercado C, Galor A, Karp CL. Comparison of topical 5-fluouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia. *Am J Ophthalmol* 2019;199:216-22.
3. Fuhrman LC, Godwin DA, Davis RA. Stability of 5-Fluorouracil in an extemporaneously compounded ophthalmic solution. *Int J Pharm Compd* 2000;4(4):320-3.